<DOC>
	<DOCNO>NCT01638000</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability mirabegron 50 mg versus ( v ) solifenacin 5 mg treatment patient OAB dissatisfy treatment due lack efficacy .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Mirabegron Compared Solifenacin Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment .</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Subject willing able complete micturition diary questionnaire correctly Subject symptom OAB ( urinary frequency urgency without urgency incontinence ) least 3 month Subject currently previously receive least one antimuscarinic agent intend treat OAB . The last antimuscarinic must take least 4 week take within 6 month prior Screening Visit Female subject breastfeeding , pregnant , intend become pregnant study , childbearing potential sexually active practice highly reliable method birth control Subject neurogenic bladder Subject significant stress incontinence mixed stress/urgency incontinence stress predominant factor determine investigator ( female subject confirm cough provocation test ) Subject indwell catheter practice intermittent selfcatheterization Subject diabetic neuropathy Subject evidence symptomatic urinary tract infection , chronic inflammation interstitial cystitis , bladder stone , previous pelvic radiation therapy previous current malignant disease pelvic organ Subject uncontrolled narrow angle glaucoma , urinary gastric retention , severe ulcerative colitis , toxic megacolon , myasthenia gravis medical condition make use anticholinergic contraindicate The subject currently receive history treatment intravesical botulinum toxin ( cosmetic use acceptable ) resiniferatoxin within 9 month prior screen Subject receives nondrug treatment include electrostimulation therapy ( exception bladder training program pelvic floor exercise start 30 day prior screen ) Subject moderate severe hepatic impairment Subject severe renal impairment end stage renal disease Subject severe uncontrolled hypertension Subject clinically significant abnormal electrocardiogram ( ECG ) know history QT prolongation currently take medication know prolong QT interval Subject know suspected hypersensitivity solifenacin , mirabegron inactive ingredient Subject concurrent malignancy history cancer ( except noninvasive skin cancer ) within last 5 year prior screen Subject treat experimental device within 30 day receive experimental agent within long 30 day five halflives Subject use prohibited medication stop safely Screening Visit . Subject exclude use restrict medication meet protocolspecified criterion Subject 's last antimuscarinic treatment solifenacin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Vesitrim</keyword>
	<keyword>Frequency</keyword>
	<keyword>Urgency</keyword>
	<keyword>Urgency incontinence</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Overactive Bladder ( OAB )</keyword>
	<keyword>Micturition</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>YM178</keyword>
	<keyword>Vesicare</keyword>
	<keyword>Solifenacin</keyword>
</DOC>